Grant ID RP230072
Awarded On February 15, 2023
Title Studying and therapeutically targeting ferroptosis liability in BRCA1 deficient cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Boyi Gan
Cancer Sites All Sites
Contracted Amount $1,050,000
Lay Summary

Mutations in the tumor suppressor BRCA1 predispose to pancreatic, prostate, colorectal, and most notably, breast and ovarian cancers. Currently, inhibitors of poly (ADP-ribose) polymerase (PARPi) are used to treat cancer patients with BRCA1 deficiency; however, 40%-60% of these patients do not have a response to PARPi. Thus, novel combination treatments for patients with BRCA1-deficient cancers that are resistant to PARPi are urgently needed. Ferroptosis is an iron-dependent form of nonapoptotic cell death that is induced by a type of lipid damage on cellular membranes called lipid peroxidation. Certain drugs known as ferroptosis inducers can have potent cell killing effects by inducing fer...

Read More